

*Name of Committee:* National Library of Medicine Special Emphasis Panel, K22.

*Date:* July 20, 2006

*Time:* 1 p.m. to 2:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Library of Medicine, 6705 Rockledge Drive, Suite 301, Bethesda, MD 20892. (Telephone Conference Call).

*Contact Person:* Zoe E. Huange, MD, Health Science Administrator, Extramural Programs, National Library of Medicine, 6705 Rockledge Drive, Suite 301, Bethesda, MD 20892-7968. 301-594-4937. [huangz@mail.nih.gov](mailto:huangz@mail.nih.gov).

*Name of Committee:* National Library of Medicine Special Emphasis Panel, G08/K99/R01.

*Date:* July 27, 2006.

*Time:* 12:30 p.m. to 3:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Library of Medicine, 6705 Rockledge Drive, Suite 301, Bethesda, MD 20892. (Telephone Conference Call).

*Contact Person:* Zoe E. Huange, MD, Health Science Administrator, Extramural Programs, National Library of Medicine, 6705 Rockledge Drive, Suite 301, Bethesda, MD 20892-7968. 301-594-4937. [huangz@mail.nih.gov](mailto:huangz@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.879, Medical Library Assistance, National Institutes of Health, HHS)

Dated: May 5, 2006.

**Anna Snouffer,**

*Acting Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 06-4446 Filed 5-11-06; 8:45am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Center for Scientific Review Special Emphasis Panel, June 14, 2006, 2 p.m. to June 14, 2006, 5 p.m., National Institutes of Health, 6701 Rockledge Drive, Bethesda, MD 20892 which was published in the **Federal Register** on April 28, 2006, 71 FR 25181-25184.

The meeting will be held on June 13, 2006. The meeting time and location remain the same. The meeting is closed to the public.

Dated: May 5, 2006.

**Anna Snouffer,**

*Acting Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 06-4445 Filed 5-11-06; 8:45am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center For Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Surgery, Anesthesiology and Trauma Study Section, June 14, 2006, 1 p.m. to June 15, 2006, 3 p.m., Holiday Inn Select Bethesda, 8120 Wisconsin Ave., Bethesda, MD 20814 which was published in the **Federal Register** on May 3, 2006, 71 FR 26105-26106.

The meeting will be held at the DoubleTree Hotel, 8120 Wisconsin Avenue, Bethesda, MD 20814. The meeting dates and time remain the same. The meeting is closed to the public.

Dated: May 5, 2006.

**Anna Snouffer,**

*Acting Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 06-4458 Filed 5-11-06; 8:45am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Synthetic and Biological Chemistry B Study Section, June 8, 2006, 8:30 a.m. to June 9, 2006, 6 p.m., Holiday Inn Select Bethesda, 8120 Wisconsin Ave, Bethesda, MD, 20814 which was published in the **Federal Register** on April 25, 2006, 71 FR 23929-23931.

The meeting will be held at the Double Tree Hotel, 8120 Wisconsin Avenue Bethesda, MD 20814. The meeting dates and time remain the same. The meeting is closed to the public.

Dated: May 5, 2006.

**Anna Snouffer,**

*Acting Director, Office of Federal Advisory Committee Policy.*

[FR Doc. 06-4459 Filed 5-11-06; 8:45am]

**BILLING CODE 4140-01-M**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Substance Abuse and Mental Health Services Administration

#### Current List of Laboratories Which Meet Minimum Standards To Engage in Urine Drug Testing for Federal Agencies

**AGENCY:** Substance Abuse and Mental Health Services Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Department of Health and Human Services (HHS) notifies Federal agencies of the laboratories currently certified to meet the standards of Subpart C of the Mandatory Guidelines for Federal Workplace Drug Testing Programs (Mandatory Guidelines). The Mandatory Guidelines were first published in the **Federal Register** on April 11, 1988 (53 FR 11970), and subsequently revised in the **Federal Register** on June 9, 1994 (59 FR 29908), on September 30, 1997 (62 FR 51118), and on April 13, 2004 (69 FR 19644).

A notice listing all currently certified laboratories is published in the **Federal Register** during the first week of each month. If any laboratory's certification is suspended or revoked, the laboratory will be omitted from subsequent lists until such time as it is restored to full certification under the Mandatory Guidelines.

If any laboratory has withdrawn from the HHS National Laboratory Certification Program (NLCP) during the past month, it will be listed at the end, and will be omitted from the monthly listing thereafter.

This notice is also available on the Internet at <http://workplace.samhsa.gov> and <http://www.drugfreeworkplace.gov>.

**FOR FURTHER INFORMATION CONTACT:** Mrs. Giselle Hersch or Dr. Walter Vogl, Division of Workplace Programs, SAMHSA/CSAP, Room 2-1035, 1 Choke Cherry Road, Rockville, Maryland 20857; 240-276-2600 (voice), 240-276-2610 (fax).

**SUPPLEMENTARY INFORMATION:** The Mandatory Guidelines were developed in accordance with Executive Order 12564 and section 503 of Public Law 100-71. Subpart C of the Mandatory Guidelines, "Certification of Laboratories Engaged in Urine Drug Testing for Federal Agencies," sets strict standards that laboratories must meet in order to conduct drug and specimen validity tests on urine specimens for Federal agencies. To become certified, an applicant laboratory must undergo three rounds of performance testing plus an on-site inspection. To maintain that

certification, a laboratory must participate in a quarterly performance testing program plus undergo periodic, on-site inspections.

Laboratories which claim to be in the applicant stage of certification are not to be considered as meeting the minimum requirements described in the HHS Mandatory Guidelines. A laboratory must have its letter of certification from HHS/SAMHSA (formerly: HHS/NIDA) which attests that it has met minimum standards.

In accordance with Subpart C of the Mandatory Guidelines dated April 13, 2004 (69 FR 19644), the following laboratories meet the minimum standards to conduct drug and specimen validity tests on urine specimens:

- ACL Laboratories 8901 W. Lincoln Ave., West Allis, WI 53227, 414-328-7840 / 800-877-7016, (Formerly: Bayshore Clinical Laboratory).
- ACM Medical Laboratory, Inc., 160 Elmgrove Park, Rochester, NY 14624, 585-429-2264.
- Advanced Toxicology Network, 3560 Air Center Cove, Suite 101, Memphis, TN 38118, 901-794-5770 / 888-290-1150.
- Aegis Analytical Laboratories, Inc., 345 Hill Ave., Nashville, TN 37210, 615-255-2400.
- Baptist Medical Center-Toxicology Laboratory, 9601 I-630, Exit 7, Little Rock, AR 72205-7299, 501-202-2783, (Formerly: Forensic Toxicology Laboratory Baptist Medical Center)
- Clinical Reference Lab, 8433 Quivira Road, Lenexa, KS 66215-2802 800-445-6917.
- Diagnostic Services, Inc., dba DSI, 12700 Westlinks Drive, Fort Myers, FL 33913, 239-561-8200 / 800-735-5416.
- Doctors Laboratory, Inc., 2906 Julia Drive, Valdosta, GA 31602, 229-671-2281.
- DrugScan, Inc., P.O. Box 2969, 1119 Mearns Road, Warminster, PA 18974, 215-674-9310.
- Dynacare Kasper Medical Laboratories\*, 10150-102 St., Suite 200 Edmonton, Alberta Canada T5J 5E2, 780-451-3702 / 800-661-9876.
- ElSohly Laboratories, Inc., 5 Industrial Park Drive, Oxford, MS 38655, 662-236-2609.
- Express Analytical Labs, 3405 7th Ave., Suite 106, Marion, IA 52302, 319-377-0500.
- Gamma-Dynacare Medical Laboratories\*, A Division of the Gamma-Dynacare, Laboratory Partnership, 245 Pall Mall Street, London, ONT, Canada N6A 1P4, 519-679-1630.
- General Medical Laboratories, 36 South Brooks St., Madison, WI 53715, 608-267-6225.
- Kroll Laboratory Specialists, Inc., 1111 Newton St., Gretna, LA 70053, 504-361-8989/800-433-3823, (Formerly: Laboratory Specialists, Inc.).
- Kroll Scientific Testing Laboratories, Inc., 450 Southlake Blvd., Richmond, VA 23236, 804-378-9130, (Formerly: Scientific Testing Laboratories, Inc.).
- Laboratory Corporation of America Holdings, 7207 N. Gessner Road, Houston, TX 77040, 713-856-8288/800-800-2387.
- Laboratory Corporation of America Holdings, 69 First Ave., Raritan, NJ 08869, 908-526-2400/800-437-4986, (Formerly: Roche Biomedical Laboratories, Inc.).
- Laboratory Corporation of America Holdings, 1904 Alexander Drive, Research Triangle Park, NC 27709, 919-572-6900/800-833-3984, (Formerly: LabCorp Occupational Testing Services, Inc., CompuChem Laboratories, Inc.; CompuChem Laboratories, Inc., A Subsidiary of Roche Biomedical Laboratory; Roche CompuChem Laboratories, Inc., A Member of the Roche Group).
- Laboratory Corporation of America Holdings, 10788 Roselle St., San Diego, CA 92121, 800-882-7272, (Formerly: Poisonlab, Inc.).
- Laboratory Corporation of America Holdings, 550 17th Ave., Suite 300, Seattle, WA 98122, 206-923-7020/800-898-0180, (Formerly: DrugProof, Division of Dynacare/Laboratory of Pathology, LLC; Laboratory of Pathology of Seattle, Inc.; DrugProof, Division of Laboratory of Pathology of Seattle, Inc.).
- Laboratory Corporation of America Holdings, 1120 Main Street, Southaven, MS 38671, 866-827-8042/800-233-6339, (Formerly: LabCorp Occupational Testing Services, Inc.; MedExpress/National Laboratory Center).
- Marshfield Laboratories, Forensic Toxicology Laboratory, 1000 North Oak Ave., Marshfield, WI 54449, 715-389-3734/ 800-331-3734.
- MAXXAM Analytics Inc.\*, 6740 Campobello Road, Mississauga, ON, Canada L5N 2L8, 905-817-5700, (Formerly: NOVAMANN (Ontario), Inc.).
- MedTox Laboratories, Inc., 402 W. County Road D, St. Paul, MN 55112, 651-636-7466/800-832-3244.
- MetroLab-Legacy Laboratory Services, 1225 NE 2nd Ave., Portland, OR 97232, 503-413-5295/800-950-5295.
- Minneapolis Veterans Affairs Medical Center, Forensic Toxicology Laboratory, 1 Veterans Drive, Minneapolis, MN 55417, 612-725-2088.
- National Toxicology Laboratories, Inc., 1100 California Ave., Bakersfield, CA 93304, 661-322-4250/800-350-3515.
- One Source Toxicology Laboratory, Inc., 1213 Genoa-Red Bluff, Pasadena, TX 77504, 888-747-3774, (Formerly: University of Texas Medical Branch, Clinical Chemistry Division; UTMB Pathology-Toxicology Laboratory).
- Oregon Medical Laboratories, 123 International Way, Springfield, OR 97477, 541-341-8092.
- Pacific Toxicology Laboratories, 9348 DeSoto Ave., Chatsworth, CA 91311, 800-328-6942, (Formerly: Centinela Hospital Airport Toxicology Laboratory).
- Pathology Associates Medical Laboratories, 110 West Cliff Dr., Spokane, WA 99204, 509-755-8991/800-541-7897x7.
- Physicians Reference Laboratory, 7800 West 110th St., Overland Park, KS 66210, 913-339-0372/800-821-3627.
- Quest Diagnostics Incorporated, 3175 Presidential Dr., Atlanta, GA 30340, 770-452-1590/800-729-6432, (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories).
- Quest Diagnostics Incorporated, 4770 Regent Blvd., Irving, TX 75063, 800-824-6152, (Moved from the Dallas location on 03/31/01; Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories).
- Quest Diagnostics Incorporated, 4230 South Burnham Ave., Suite 250, Las Vegas, NV 89119-5412, 702-733-7866/800-433-2750, (Formerly: Associated Pathologists Laboratories, Inc.).
- Quest Diagnostics Incorporated, 10101 Renner Blvd., Lenexa, KS 66219, 913-888-3927/800-873-8845, (Formerly: LabOne, Inc.; Center for Laboratory Services, a Division of LabOne, Inc.).
- Quest Diagnostics Incorporated, 400 Egypt Road, Norristown, PA 19403, 610-631-4600/877-642-2216, (Formerly: SmithKline Beecham Clinical Laboratories; SmithKline Bio-Science Laboratories).
- Quest Diagnostics Incorporated, 506 E. State Pkwy., Schaumburg, IL 60173, 800-669-6995/847-885-2010, (Formerly: SmithKline Beecham Clinical Laboratories; International Toxicology Laboratories).
- Quest Diagnostics Incorporated, 7600 Tyrone Ave., Van Nuys, CA 91405, 866-370-6699/818-989-2521, (Formerly: SmithKline Beecham Clinical Laboratories).
- Quest Diagnostics Incorporated, 2282 South Presidents Drive, Suite C, West Valley City, UT 84120, 801-606-6301/800-322-3361, (Formerly: Northwest Toxicology, a LabOne Company; LabOne, Inc., dba Northwest Toxicology; NWT Drug Testing, NorthWest Toxicology, Inc.; Northwest Drug Testing, a division of NWT Inc.).
- S.E.D. Medical Laboratories, 5601 Office Blvd., Albuquerque, NM 87109, 505-727-6300/800-999-5227.
- South Bend Medical Foundation, Inc., 530 N. Lafayette Blvd., South Bend, IN 46601, 574-234-4176 x276.
- Southwest Laboratories, 4645 E. Cotton Center Boulevard, Suite 177, Phoenix, AZ 85040, 602-438-8507/800-279-0027.
- Sparrow Health System, Toxicology Testing Center, St. Lawrence Campus, 1210 W. Saginaw, Lansing, MI 48915, 517-364-7400, (Formerly: St. Lawrence Hospital & Healthcare System).
- St. Anthony Hospital Toxicology Laboratory, 1000 N. Lee St., Oklahoma City, OK 73101, 405-272-7052.
- Toxicology & Drug Monitoring Laboratory, University of Missouri Hospital &

Clinics, 301 Business Loop 70 West,  
Suite 208, Columbia, MO 65203, 573-  
882-1273.

Toxicology Testing Service, Inc., 5426 N.W.  
79th Ave., Miami, FL 33166, 305-593-  
2260.

US Army Forensic Toxicology Drug Testing  
Laboratory, 2490 Wilson St., Fort George  
G. Meade, MD 20755-5235, 301-677-  
7085.

The following laboratory's  
certification was suspended on  
November 14, 2005, with an effective  
date of November 15, 2005, and then  
revoked on February 8, 2006:

Sciteck Clinical Laboratories, Inc., 317  
Rutledge Road, Fletcher, NC 28732, 828-  
650-0409.

\* The Standards Council of Canada (SCC)  
voted to end its Laboratory Accreditation  
Program for Substance Abuse (LAPSA)  
effective May 12, 1998. Laboratories certified  
through that program were accredited to  
conduct forensic urine drug testing as  
required by U.S. Department of  
Transportation (DOT) regulations. As of that  
date, the certification of those accredited  
Canadian laboratories will continue under  
DOT authority. The responsibility for  
conducting quarterly performance testing  
plus periodic on-site inspections of those  
LAPSA-accredited laboratories was  
transferred to the U.S. HHS, with the HHS'  
NLCP contractor continuing to have an active  
role in the performance testing and  
laboratory inspection processes. Other  
Canadian laboratories wishing to be  
considered for the NLCP may apply directly  
to the NLCP contractor just as U.S.  
laboratories do.

Upon finding a Canadian laboratory to  
be qualified, HHS will recommend that  
DOT certify the laboratory (**Federal  
Register**, July 16, 1996) as meeting the  
minimum standards of the Mandatory  
Guidelines published in the **Federal  
Register** on April 13, 2004 (69 FR  
19644). After receiving DOT  
certification, the laboratory will be  
included in the monthly list of HHS-  
certified laboratories and participate in  
the NLCP certification maintenance  
program.

**Anna Marsh,**  
*Director, Office Program Services, SAMHSA.*  
[FR Doc. E6-7316 Filed 5-11-06; 8:45 am]

**BILLING CODE 4160-20-P**

## DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-5045-N-19]

### Federal Property Suitable as Facilities To Assist the Homeless

**AGENCY:** Office of the Assistant  
Secretary for Community Planning and  
Development, HUD.

**ACTION:** Notice.

**SUMMARY:** This Notice identifies  
unutilized, underutilized, excess, and  
surplus Federal property reviewed by  
HUD for suitability for possible use to  
assist the homeless.

**DATES:** *Effective Date:* May 12, 2006.

**FOR FURTHER INFORMATION CONTACT:**  
Kathy Ezzell, Department of Housing  
and Urban Development, Room 7262,  
451 Seventh Street SW., Washington,  
DC 20410; telephone (202) 708-1234;  
TTY number for the hearing- and  
speech-impaired (202) 708-2565, (these  
telephone numbers are not toll-free), or  
call the toll-free title V information line  
at 1-800-927-7588.

**SUPPLEMENTARY INFORMATION:** In  
accordance with the December 12, 1988  
court order in *National Coalition for the  
Homeless v. Veterans Administration*,  
No. 88-2503-OG (D.D.C.), HUD  
publishes a Notice, on a weekly basis,  
identifying unutilized, underutilized,  
excess and surplus Federal buildings  
and real property that HUD has  
reviewed for suitability for use to assist  
the homeless. Today's Notice is for the  
purpose of announcing that no  
additional properties have been  
determined suitable or unsuitable this  
week.

Dated: May 4, 2006.

**Mark R. Johnston,**  
*Acting Deputy Assistant Secretary for Special  
Needs.*

[FR Doc. 06-4318 Filed 5-11-06; 8:45am]

**BILLING CODE 4210-67-M**

## INTERNATIONAL TRADE COMMISSION

[Inv. No. 337-TA-568]

### In the Matter of Certain Products and Pharmaceutical Compositions Containing Recombinant Human Erythropoietin; Notice of Investigation

**AGENCY:** U.S. International Trade  
Commission.

**ACTION:** Institution of investigation  
pursuant to 19 U.S.C. 1337.

**SUMMARY:** Notice is hereby given that a  
complaint was filed with the U.S.  
International Trade Commission on  
April 11, 2006, under section 337 of the  
Tariff Act of 1930, as amended, 19  
U.S.C. 1337, on behalf of Amgen Inc. of  
Thousand Oaks, California. Amgen filed  
an amended complaint and a  
supplement on April 27, 2006. The  
amended complaint alleges violations of  
section 337 in the importation into the  
United States of certain products and  
pharmaceutical compositions

containing recombinant human  
erythropoietin by reason of infringement  
of claims 1 and 2 of U.S. Patent No.  
5,441,868, claims 3, 4, 5, and 11 of U.S.  
Patent No. 5,547,933, claims 4-9 of U.S.  
Patent No. 5,618,698, claims 4 and 6 of  
U.S. Patent No. 5,621,080, claim 7 of  
U.S. Patent No. 5,756,349, and claim 1  
of U.S. Patent No. 5,955,422. The  
complaint further alleges that an  
industry in the United States exists as  
required by subsection (a)(2) of section  
337.

The complainant requests that the  
Commission institute an investigation  
and, after the investigation, issue a  
permanent exclusion order and  
permanent cease and desist orders.

**ADDRESSES:** The amended complaint,  
except for any confidential information  
contained therein, is available for  
inspection during official business  
hours (8:45 a.m. to 5:15 p.m.) in the  
Office of the Secretary, U.S.  
International Trade Commission, 500 E  
Street, SW., Room 112, Washington, DC  
20436, telephone 202-205-2000.  
Hearing impaired individuals are  
advised that information on this matter  
can be obtained by contacting the  
Commission's TDD terminal on 202-  
205-1810. Persons with mobility  
impairments who will need special  
assistance in gaining access to the  
Commission should contact the Office  
of the Secretary at 202-205-2000.  
General information concerning the  
Commission may also be obtained by  
accessing its Internet server at <http://www.usitc.gov>. The public record for  
this investigation may be viewed on the  
Commission's electronic docket (EDIS)  
at <http://edis.usitc.gov>.

**FOR FURTHER INFORMATION CONTACT:**  
Anne Goalwin, Office of Unfair Import  
Investigations, U.S. International Trade  
Commission, telephone (202) 205-2574.

**Authority:** The authority for institution of  
this investigation is contained in section 337  
of the Tariff Act of 1930, as amended, and  
in section 210.10 of the Commission's Rules  
of Practice and Procedure, 19 CFR 210.10  
(2005).

**Scope of Investigation:** Having  
considered the complaint, the U.S.  
International Trade Commission, on  
May 8, 2006, *ordered that*—

(1) Pursuant to subsection (b) of  
section 337 of the Tariff Act of 1930, as  
amended, an investigation be instituted  
to determine whether there is a  
violation of subsection (a)(1)(B) of  
section 337 in the importation into the  
United States, the sale for importation,  
or the sale within the United States after  
importation of certain products and  
pharmaceutical compositions  
containing recombinant human